BioNTech (BNTX) vs Vaxcyte (PCVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Vaxcyte (PCVX) has outperformed BioNTech (BNTX) over the past year, gaining 70.0% versus a loss of 7.2%. Over five years, PCVX leads with a +192.4% price change compared with -60.9% for BNTX. BioNTech is the larger company by market cap ($24.36 billion vs $11.15 billion), about 2.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTX | PCVX |
|---|---|---|
| Share price | $96.96 | $71.38 |
| Market cap | $24.36B | $11.15B |
| 1-day change | +5.32% | +9.79% |
| YTD return | +1.85% | +54.70% |
| 1-year return | -7.20% | +69.99% |
| 5-year return | -60.85% | +192.42% |
| EPS (TTM) | $-7.83 | $-8.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-766.63M |
| 52-week high | $124.00 | $90.75 |
| 52-week low | $79.52 | $39.87 |
| Distance from 52-week high | -21.81% | -21.34% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +19.85% | +63.91% |
| Average volume | 1.17M | 1.76M |
| Shares outstanding | 251.20M | 156.22M |
| Employees | 7,807 | 507 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BioNTech is about 2.2 times larger than Vaxcyte by market value ($24.36B vs $11.15B).
- PCVX has outperformed BNTX by 77.2 percentage points over the past year.
About BioNTech
BNTX stock →BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees
About Vaxcyte
PCVX stock →Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 507 employees
BNTX vs PCVX FAQ
Which is bigger, BioNTech or Vaxcyte?
BioNTech (BNTX) is larger, with a market capitalization of $24.36B compared with $11.15B for Vaxcyte (PCVX).
Which stock has performed better over the past year, BNTX or PCVX?
PCVX returned +69.99% over the past 12 months, compared with -7.20% for BNTX (price return, excluding dividends). Past performance does not predict future results.
Are BioNTech and Vaxcyte in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.